News

It is good to see, that FluoGuide A/S is on track with the clinical trial investigating FG001 in head and neck cancer. We very much look forward to getting interim data within the next 6 - 8 month.

At Global Cardiovascular Awards 2025 in London, Acarix received the award for best digital innovation with the CADScor system.
The Global Cardiovascular Awards are judged by a panel of international experts in cardiovascular and cardiothoracic medicine.
We congratulate Acarix with this achievement which underlines the scope of what CADScor can do to...

AcuCort AB has today announced the final result of the rights issue, and with a subscription rate of 160 %, it was heavily oversubscriped, which is rarely seen these days. AcuCort AB will be receiving 47,7 mio. SEK brutto and at least 41 mio. SEK netto.
As previously communicated, in line with our long-term partner strategy, LSIF has also...

BiBBInstruments AB has announced the final outcome of its rights issue, and as was the aim for LSIF acting as lead guarantor, LSIF becomes a major shareholder in BiBBInstruments AB. LSIF looks forward to participate in the commercialisation journey for BiBBInstruments AB. We believe, that the EndoDrill system has the potential to become the new...

Lipidor has announced, that 50% of the patients in the ongoing Phase III study for the drug candidate AKP02G2 have now been enrolled. This marks a milestone in the study, and due to an accelerated enrollment as the number of participating clinics grow, the company expects to have the result of the study as soon as in April 2025.

As communicated to the market yesterday, LSIF has decided to further support the ongoing capital round in AcuCort AB by committing to subscribe for an additional approx. SEK 2,28 mio. bringing our total maximum commitment including guarentees in this round to SEK 12,25 mio. We do this because of our strong belief in AcuCort AB which underlines...

At LSIF we are pleased to see that FluoGuide A/S has now recieved approval for the phase II trial in head and neck cancer taking the next step for FG001. Enrollment of the needed 25 - 30 patients starts this quarter and interrim data is expected in H2 2025. It will be interesting to hopefully soon get news regarding partners...

A few days ago PMD Solutions filed for banktruptcy just 3 month after receiving SEK 17 mio. net from investors including LSIF.
In retrospect, it was obviously a mistake to invest in PMD, where almost from day 1 after the investment surprising issues both financially and legally appeared.
LSIF has managed to reduce the loss, but will still...

Prostatype Genomics AB announces very high subscription rate.
From the outstanding TO4 approximately 93.6 % were exercised including 5 % from the Top Guarantee. This constitutes an impressing support from the shareholders, and Life Science Invest Fund (LSIF) is pleased to announce, that we, being a major shareholder, subscribed to our pro rata...

Prostatype Genomics AB has this morning announced an order of 1.3 mio. SEK to University Hospital Policlinico Tor Vergata in Rome. It is encouraging to see, that Associate Professor Pierluigi Bove, a respected Italian urologist and Giuseppe Novelli, Head of the Human Genetics Research Unit both endorse the test from Prostatype Genomics AB by...